Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Internal medicine physician Dr. Frank Dumont, executive medical director at Virta Health in San Francisco, outlined six potential risks patients may face after discontinuing GLP-1 medications such as Ozempic, Wegovy, and Zepbound, speaking with Fox News Digital. Research shows many patients stop taking these drugs within a year due to side effects like nausea, vomiting, and diarrhea, or because they prefer not to remain on long-term medication. Dr. Dumont noted that serious side effects such as acute pancreatitis, though rare, prompt immediate discontinuation, and the drugs carry warnings about thyroid tumors based on animal studies.
The first risk is the return of intense cravings and a sharp spike in appetite, often called "food noise." Dr. Dumont said, "Unless you have significantly changed what you're doing in terms of the types of foods you're eating, it's likely you'll go back to the same foods you were eating before, and hunger and cravings will go up." Major medical organizations including the American Medical Association and the Obesity Medicine Association classify obesity as a chronic condition requiring ongoing management.
Second, weight regain is typical. In the STEP 1 trial extension, participants regained about two-thirds of lost weight within a year of stopping semaglutide and lifestyle interventions. In the SURMOUNT-4 trial for tirzepatide, patients switched to placebo after 36 weeks regained more than half the lost weight over the following year, even with diet and exercise counseling. Dr. Dumont called this "devastating for people who felt like they'd finally found a solution that would work."
Third, biomarkers such as blood sugar, blood pressure, and cholesterol levels — which improve during treatment — can reverse if diet is not changed. Improvements in fatty liver disease may also fade. Dr. Dumont said, "When you go off the medicine, if you go back to eating the way you did before, those numbers have a tendency to worsen."
Fourth, weight loss on GLP-1s includes loss of lean muscle mass. In a body-composition study of tirzepatide, about 25% of weight lost was lean mass. Dr. Dumont warned of a "ratcheting-down effect" where patients lose fat and muscle, regain fat after stopping, then lose fat and muscle again upon restarting, compromising metabolism and physical function.
Fifth, stopping can take a heavy toll on mental health. Patients who view GLP-1s as a final solution after years of failed diets may experience a "regression on all fronts" that is "really devastating from a mental health standpoint," making them feel disheartened and out of control.
Sixth, an observational study published in BMJ Medicine found adults with type 2 diabetes who stopped GLP-1 treatment had a higher risk of major cardiovascular events than those who continued, with longer periods off treatment associated with greater risk. Dr. Dumont emphasized that lower inflammation and improved cholesterol and blood sugar during treatment reduce risks of heart attacks and strokes, but stopping without dietary changes can worsen these markers and increase risk. He concluded, "The GLP-1 is not the only solution. It needs to be coupled with ... a way of eating that's going to work for you for the long term that allows you to stop the medicine successfully if you need to."
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 3d ago.
Quick answers
What are the six rebound risks Dr. Dumont identified after stopping GLP-1 medications?
The six risks are: return of intense cravings and appetite ("food noise"); rapid weight regain; reversal of improved biomarkers like blood sugar, blood pressure, cholesterol, and fatty liver markers; loss of lean muscle mass during weight loss that may not be fully regained; negative mental health effects including feeling disheartened and out of control; and increased risk of major cardiovascular events such as heart attack and stroke.
How much weight do patients typically regain after stopping semaglutide or tirzepatide?
In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide and lifestyle interventions. In the SURMOUNT-4 trial for tirzepatide, patients switched to placebo after 36 weeks regained more than half the lost weight over the following year, even with diet and exercise counseling.
Why do patients stop taking GLP-1 medications according to Dr. Dumont?
Patients stop due to side effects like nausea, vomiting, and diarrhea that can make it hard to eat enough for good nourishment; serious but rare side effects like acute pancreatitis; thyroid tumor warnings based on animal studies; and a preference not to remain on long-term medication.
Coverage (18)
- What Happens to the Heart When You Stop Using the “Weight Loss Injection”? Yahoo Life UK · 3d ago
- 'Double heart attack risk' warning for people on Wegovy and Mounjaro The Mirror · 3d ago
- Stopping weight-loss drugs may double heart attack, stroke and death risk, study finds The Indian Express · 3d ago
- Stopping GLP-1 linked to nearly twice the rate of adverse events UA.NEWS · 3d ago
- GLP-1 users face 6 rebound risks after stopping the weight-loss drugs New York Post · 3d ago
- Stopping weight loss drugs doubles diabetics’ heart attack risk The Telegraph · 3d ago
- GLP-1 users who stop taking medication face doubled risk of heart attack, stroke or death: study CP24 · 3d ago
- Type 2 diabetes patients ‘may risk heart issues if they stop weight-loss jabs’ Doctors.net.uk · 3d ago
- Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns Yahoo Health · 3d ago
- Stopping GLP-1s linked to twice the risk of heart attack, stroke or death in type 2 diabetes The Pharmaceutical Journal · 3d ago
- Stopping Weight-Loss Injections May Double Heart Attack and Stroke Risk Pharmacy Business · 3d ago
- Doctor outlines six potential risks of stopping GLP-1 drugs Mezha.net · 3d ago
- Stopping GLP-1 drugs could increase heart attack risk for some, study says Global News · 3d ago
- Stopping Ozempic may be bad for your health Medical Xpress · 3d ago
- New study uncovers little-known risk of stopping weight-loss injections The Independent · 3d ago
- Coming off GLP-1s linked to double heart attack, stroke, death risk Euronews.com · 3d ago
- GLP-1 users who stop taking medication face doubled risk of heart attack, stroke or death: study CTV News · 3d ago
- Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns Fox News · 3d ago
Topics
Related trends
Hundreds of children in England prescribed weight-loss jabs, figures show
Recent figures reveal hundreds of children in England are receiving GLP-1 weight-loss prescriptions.
Makers of obesity drugs hit back at claims of negative side effects
Makers of blockbuster weight loss drugs defend product safety amid mounting scrutiny over potential side effects.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.